News | 12 October 2024
Akums launches dual action heartburn relief chewable tablet
This product is categorized as antacids, antiflatulents and anti-Ulcerants
This product is categorized as antacids, antiflatulents and anti-Ulcerants
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
Under the licensing agreement, Alkem will carry out the clinical development of “SON-080” in India with support from Sonnet and enable global and India regulatory filings
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
Aims to achieve CDMO sales of US$ 400 million by 2028
We now rank 3rd in pharmaceutical production by volume and 14th by value
Biotin Sublingual Spray and Melatonin Sublingual Spray to help consumers tackle health issues that come with today’s fast-paced life
WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Strategic focus on COCO-model with a nationwide reach of 501 stores
CSPC will receive an upfront payment of $100 million from AstraZeneca
The OPTASE range is a safe, tested and expert recommended 3-step regime to help tackle the cause and symptoms of eye conditions
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
The acquisition will strengthen the overall company’s position as leading global CRO services partner
he company will focus on production of any pharmaceutical and biotechnological products
USFDA completes PAI of Lupin’s biotech facility in Pune
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Subscribe To Our Newsletter & Stay Updated
